Clinical Trial Update: Immune Response on Neoadjuvant Therapy in Non-small-cell Lung Cancer (NSCLC) [Phase 2]

View source ↗

Summary

A Phase 2 neoadjuvant trial in non-small cell lung cancer has completed, reporting on immune responses observed during treatment.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Snippet

Sponsor: Wolfgang Hilbe | Conditions: Carcinoma, Non-small-cell Lung | Phase 2 | Status: COMPLETED